Newsroom
News Releases
2011
2010
2009
01.13.12
J.P.Morgan Presentation Focused on Three Transformational Programs for 2012 PDF 165KB
11.21.11
Portola Pharmaceuticals Announces Completion of $89 Million Financing PDF 58KB
10.27.11
Biogen Idec and Portola Pharmaceuticals announce global collaboration for oral SYK inhibitor PDF 117KB
8.11.11
Portola Pharmaceuticals Announces Factor Xa Inhibitor Antidote Data at ESC 2011 Congress PDF 93KB
7.18.11
Portola Pharmaceuticals Announces Appointment of Dr Michael Kitt as Chief Medical Officer PDF 93KB
4.12.11
Portola Pharmaceuticals Announces Appointment of Dr. James Topper to Board of Directors PDF 65KB
3.31.11
Portola Pharmaceuticals Announces Phase 1 Multiple Ascending Dose Trial of Oral Syk Inhibitor PDF 30KB
3.24.11
Portola Pharmaceuticals Announces Regain of Global Rights for Betrixaban from Merck PDF 65KB
1.24.11
Portola Pharmaceuticals Appoints John T. Curnutte, M.D., Ph.D., to Head R&D PDF 45KB
1.05.11
Portola Pharmaceuticals Announces Presentation at J.P. Morgan’s 29th Annual Healthcare Conference PDF 126KB
12.04.10
Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program PDF 88KB
11.15.10
Portola Pharmaceuticals Announces Investigational Universal Factor Xa Inhibitor Antidote Reverses Anticoagulant Activity of Factor Xa Inhibitors PDF 128KB
9.23.10
Portola Pharmaceuticals Appoints Jean-Jacques Bienaimé to Board of Directors PDF 48KB
8.30.10
Portola Pharmaceuticals Announces that Phase 2 INNOVATE-PCI Trial with Elinogrel Achieved Objectives PDF 45KB
8.29.10
Portola Pharmaceuticals Announces Presentation of New Pharmacodynamic Data from Phase 2 Trial of Investigational Factor Xa Inhibitor, Betrixaban PDF 45KB
3.22.10
Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications PDF 49KB
3.15.10
Portola Pharmaceuticals and Merck Announce the Results of EXPLORE-Xa PDF 65KB
3.11.10
Portola Pharmaceuticals Announces Senior Management and Board Changes PDF 50KB
2.10.10
Portola Pharmaceuticals Announces Late-Breaker Presentation on Betrixaban PDF 71KB
9.24.09
Portola Pharmaceuticals Announces Promotions of Senior Management Team PDF 30KB
8.24.09
Portola Pharmaceuticals Announces Two Oral Presentations on Elinogrel at European Society of Cardiology Congress 2009 PDF 26KB
7.10.09
Portola Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress PDF 34KB
7.9.09
Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, a Novel Investigational Oral Anticoagulant for Cardiovascular Disease PDF 32KB
6.29.09
Portola announced as one of FierceBiotech's 2009 Fierce 15 PDF 96KB
2.12.09
Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel PDF 28KB